Mutations in the sonic hedgehog pathway cause macrocephaly-associated conditions due to crosstalk to the PI3K/AKT/mTOR pathway

被引:20
|
作者
Klein, Steven D. [1 ]
Nguyen, Dzung C. [1 ]
Bhakta, Viraj [1 ]
Wong, Derek [2 ]
Chang, Vivian Y. [3 ,4 ]
Davidson, Tom B. [3 ,4 ]
Martinez-Agosto, Julian A. [1 ,2 ]
机构
[1] Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Div Med Genet, Los Angeles, CA 90095 USA
[3] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Div Hematol Oncol, Los Angeles, CA 90095 USA
[4] Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA
关键词
SIGNALING PATHWAY; DUPLICATION; ACTIVATION; TARGET; NOTCH; GLI1;
D O I
10.1002/ajmg.a.61368
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
The hedgehog (Hh) pathway is highly conserved and required for embryonic patterning and determination. Mutations in the Hh pathway are observed in sporadic tumors as well as under syndromic conditions. Common to these syndromes are the findings of polydactyly/syndactyly and brain overgrowth. The latter is also a finding most commonly observed in the cases of mutations in the PI3K/AKT/mTOR pathway. We have identified novel Hh pathway mutations and structural copy number variations in individuals with somatic overgrowth, macrocephaly, dysmorphic facial features, and developmental delay, which phenotypically closely resemble patients with phosphatase and tensin homolog (PTEN) mutations. We hypothesized that brain overgrowth and phenotypic overlap with syndromic overgrowth syndromes in these cases may be due to crosstalk between the Hh and PI3K/AKT/mTOR pathways. To test this, we modeled disease-associated variants by generating PTCH1 and Suppressor of Fused (SUFU) heterozygote cell lines using the CRISPR/Cas9 system. These cells demonstrate activation of PI3K signaling and increased phosphorylation of its downstream target p4EBP1 as well as a distinct cellular phenotype. To further investigate the mechanism underlying this crosstalk, we treated human neural stem cells with sonic hedgehog (SHH) ligand and performed transcriptional analysis of components of the mTOR pathway. These studies identified decreased expression of a set of mTOR negative regulators, leading to its activation. We conclude that there is a significant crosstalk between the SHH and PI3K/AKT/mTOR. We propose that this crosstalk is responsible for why mutations in PTCH1 and SUFU lead to macrocephaly phenotypes similar to those observed in PTEN hamartoma and other overgrowth syndromes associated with mutations in PI3K/AKT/mTOR pathway genes.
引用
收藏
页码:2517 / 2531
页数:15
相关论文
共 50 条
  • [41] PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma
    Li, Xiaoman
    Wu, Changjing
    Chen, Nianci
    Gu, Huadi
    Yen, Allen
    Cao, Liu
    Wang, Enhua
    Wang, Liang
    ONCOTARGET, 2016, 7 (22) : 33440 - 33450
  • [42] Interaction of ncRNAs and the PI3K/AKT/mTOR pathway: Implications for osteosarcoma
    Shao, Weilin
    Feng, Yan
    Huang, Jin
    Li, Tingyu
    Gao, Shengguai
    Yang, Yihao
    Li, Dongqi
    Yang, Zuozhang
    Yao, Zhihong
    OPEN LIFE SCIENCES, 2024, 19 (01):
  • [43] The PI3K/AKT/mTOR Pathway as a Therapeutic Target in Endometrial Cancer
    Slomovitz, Brian M.
    Coleman, Robert L.
    CLINICAL CANCER RESEARCH, 2012, 18 (21) : 5856 - 5864
  • [44] The PI3K/AKT/mTOR pathway in the pathophysiology and treatment of pituitary adenomas
    Monsalves, Eric
    Juraschka, Kyle
    Tateno, Toru
    Agnihotri, Sameer
    Asa, Sylvia L.
    Ezzat, Shereen
    Zadeh, Gelareh
    ENDOCRINE-RELATED CANCER, 2014, 21 (04) : R331 - R344
  • [45] Targeting the PI3K/Akt/mTOR signalling pathway in Cystic Fibrosis
    R. Reilly
    M. S. Mroz
    E. Dempsey
    K. Wynne
    S. J. Keely
    E. F. McKone
    C. Hiebel
    C. Behl
    J. A. Coppinger
    Scientific Reports, 7
  • [46] Recent syntheses of PI3K/Akt/mTOR signaling pathway inhibitors
    Welker, Mark E.
    Kulik, George
    BIOORGANIC & MEDICINAL CHEMISTRY, 2013, 21 (14) : 4063 - 4091
  • [47] The PI3K/AKT/mTOR signaling pathway in osteoarthritis: a narrative review
    Sun, K.
    Luo, J.
    Guo, J.
    Yao, X.
    Jing, X.
    Guo, F.
    OSTEOARTHRITIS AND CARTILAGE, 2020, 28 (04) : 400 - 409
  • [48] Targeting the PI3K/Akt/mTOR pathway for cancer prevention.
    Dennis, PA
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2005, 14 (11) : 2800S - 2801S
  • [49] The Role of the PI3K/AKT/mTOR Signalling Pathway in Male Reproduction
    Deng, Chun-Yan
    Lv, Mei
    Luo, Bin-Han
    Zhao, Si-Ze
    Mo, Zhong-Cheng
    Xie, Yuan-Jie
    CURRENT MOLECULAR MEDICINE, 2021, 21 (07) : 539 - 548
  • [50] The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer
    Mabuchi, Seiji
    Kuroda, Hiromasa
    Takahashi, Ryoko
    Sasano, Tomoyuki
    GYNECOLOGIC ONCOLOGY, 2015, 137 (01) : 173 - 179